GlassScriptPhysician profile
Cecelia Haines Boardman
NPI 1528158326
$576,964.91
in general payments reported to CMS, 2019-2025
36 companies · $73K in 2025
The $73K reported for 2025 was more than what 98% of Gynecologic Oncology providers received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $30K · 2021: $68K · 2022: $94K · 2023: $90K · 2024: $102K · 2025: $73K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $172K · Consulting Fee: $59K · Travel and Lodging: $27K · Food and Beverage: $7,760 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $171,775.00 |
| Consulting Fee | $58,832.25 |
| Travel and Lodging | $26,862.91 |
| Food and Beverage | $7,759.85 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $223,393.44 | 2019-2025 | Lynparza |
| Glaxosmithkline, LLC. | $145,995.58 | 2020-2025 | Jemperli, Zejula |
| Tesaro, INC. | $56,782.56 | 2019 | |
| Seagen INC. | $54,084.34 | 2020-2023 | Tivdak |
| Abbvie INC. | $36,931.44 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $23,527.16 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Genentech USA, INC. | $15,985.11 | 2019-2020 | |
| Immunogen, INC. | $10,467.69 | 2023-2024 | Elahere, Elahere |
| Genmab U.S., INC. | $5,615.61 | 2022 | |
| Pfizer INC. | $1,193.41 | 2024-2025 | |
| Eisai INC. | $1,155.95 | 2019-2025 | |
| Intuitive Surgical, INC. | $387.87 | 2022 | |
| Meditrina | $253.14 | 2025 | |
| Boston Scientific Corporation | $149.49 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $114.45 | 2023-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myriad Genetic Laboratories, INC. | $113.47 | 2020-2022 | |
| Foundation Medicine, INC. | $106.00 | 2019 | |
| Davol INC. | $89.87 | 2023-2025 | Arista, Arista Ah Flexitip |
| Tempus Ai, INC | $85.74 | 2024-2025 | Xt Cdx |
| Clovis Oncology, INC. | $79.54 | 2019-2022 | |
| Momentis Surgical INC. | $78.00 | 2022 | |
| Fennec Pharmaceuticals, INC. | $56.31 | 2025 | Fyarro |
| Caris Mpi, INC. | $53.78 | 2025 | Mi Cancer Seek |
| Cumberland Pharmaceuticals, INC. | $34.00 | 2024 | Sancuso |
| Verastem, INC. | $31.15 | 2025 | Avmapki Fakzynja Co-Pack |
| Daiichi Sankyo INC. | $29.41 | 2025 | Enhertu |
| Teleflex LLC | $24.80 | 2025 | Quikclot |
| Astellas Pharma Global Development | $23.26 | 2025 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $21.41 | 2019 | |
| Array Biopharma INC | $18.71 | 2023 | Mektovi, Braftovi |
| Ipsen Biopharmaceuticals, INC | $18.26 | 2023 | Onivyde, Somatuline Depot |
| Ethicon US, LLC | $17.53 | 2021 | |
| Baxter Healthcare | $16.80 | 2025 | Perclot |
| Janssen Pharmaceuticals, INC | $15.52 | 2023 | Xarelto |
| Tactile Systems Technology INC | $14.11 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cecelia Boardman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.